Strong Anti-Proliferative Properties Against Cancer Cells
OncoHist™ is based on research related to the novel functions of histones. Histone H1 has strong anti-proliferative properties against cancer cells of different histological origin. This has been demonstrated extensively for hematologic malignancies, such as leukemias, lymphomas and myelomas, and also for tumors from other tissues. Susceptibility of cells to the cytotoxic effect of histones is determined by the ability of histone H1 to selectively destabilize the tumor cell membrane, which results in cell death.
Instigating cell death by destabilizing the tumor cell membrane
OncoHist exhibits the same properties as naturally occurring histone H1.3 molecules and therefore has low immunogenicity and antigenicity. Extensive data suggest that OncoHist molecules have the ability to selectively destabilize the tumor cell membrane, which instigates cell death. The selective attack of the tumor cell membrane is due to OncoHist molecules ability to recognize the difference in membrane structure between tumor cells and their healthy counterparts.
OncoHist is being investigated for certain potential advantages over conventional cancer therapeutics in the areas of selectivity, toxicity, induction of resistance and immunogenicity.
Pilot Clinical Study
A pilot clinical study (Phase 1/2) with Acute Myeloid Leukemia (AML) patients was performed at the Saarland University Hospital at Homburg/Saar, Germany. OncoHist was safe and well tolerated in this study. Clinical effects were noted in seven patients with three partial remissions. Most notably, two patients who received two treatment cycles each experienced stabilization of their disease for 7 and 17 months. A clinical trial of 120 AML patients is underway in the Russian Federation. This trial aims to examine the benefits of OncoHist in combination with standard therapy: cytarabine with mitoxantrone. An additional trial for the treatment of Non-Hodgkin Lymphoma (NHL) has been initiated in Russia.
OncoHist has been granted Orphan Drug status for AML by both the FDA and EMA and for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA.
Review our key scientific publications/presentations featuring our OncoHist technology.